Cytokinetics, Incorporated
CYTK
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.0B
$72.72
▼ -1.66%
P/E
-10.07
Mkt Cap
$9.0B
52-Wk Range
$47.22–$88.31
52-Week Range
$47.22 - $88.31
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 39.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary muscle biology platform and deep cardiac/skeletal muscle physiology expertise
- Multiple late-stage clinical programs with first-in-class and best-in-class potential
- Strategic partnership with Astellas Pharma providing development and commercialization support
- Novel mechanism of action targeting muscle contractility with limited competitive landscape
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Strong growth ahead
Strong revenue growth (377% YoY)
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+7.1% over 3m
Quality
Excellent
Emerging growth company (-21% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying CYTK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of -$1.50 vs -$1.63 consensus (+8.0% surprise). Revenue of $28.6M vs $17.6M expected (+62.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+8.0%
Revenue trend · last 8Q
—
+912%
+89%
—
+318%
+5%
+1126%
-57%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$463.0K
$16.9M
$1.6M
$66.8M
$1.9M
$17.8M
$19.4M
$28.6M
Margins · last 8Q
Gross
90.0%
Operating
—
Profit
-694.4%
Wall Street consensus
11 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$115.00
▲ +58.1% vs $72.72
Latest: HC Wainwright · Aug 14, 2026
1 analyst covering
vs Industry
How CYTK stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related